NAS:ACER (USA) Also trade in: Germany

Acer Therapeutics Inc

$ 4.12 -15.16 (-78.63%)
Volume: 5,470,091 Avg Vol (1m): 158,792
Market Cap $: 41.56 Mil Enterprise Value $: 9.71 Mil
P/E (TTM): 0.00 P/B: 1.10
Earnings Power Value 1.11
Net Current Asset Value 2.91
Tangible Book 2.98
Projected FCF -17.09
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
94.06% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ACER: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 22.47, Max: 10000
Current: 10000
0
10000
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 31.33
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -459.25%
WACC 20.49%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -74.93
ROE ranked lower than
75.23% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ACER: -74.93
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -233.63, Med: -107.45, Max: -32.36
Current: -74.93
-233.63
-32.36
ROA % -68.37
ROA ranked lower than
82.56% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ACER: -68.37
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -143.94, Med: -85.41, Max: -24.27
Current: -68.37
-143.94
-24.27
ROC (Joel Greenblatt) % -21084.16
ROC (Joel Greenblatt) ranked lower than
94.50% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ACER: -21084.16
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -40431.88, Med: -1147.5, Max: -410.49
Current: -21084.16
-40431.88
-410.49
3-Year Total Revenue Growth Rate -100.00
3-Year Revenue Growth Rate ranked lower than
92.78% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ACER: -100
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -100
Current: -100
0
-100
3-Year Total EBITDA Growth Rate -21.90
3-Year EBITDA Growth Rate ranked higher than
94.39% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ACER: 50.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 19.4, Max: 67.2
Current: 50.7
0
67.2
3-Year EPS w/o NRI Growth Rate 51.00
3-Year EPS w/o NRI Growth Rate ranked higher than
92.92% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ACER: 51
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 33.1, Max: 69
Current: 51
0
69

» ACER's 30-Y Financials

Financials (Next Earnings Date: 2019-08-13)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ACER

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare OSTO:ATORX ROCO:6617 LSE:OBD ROCO:6589 NAS:EVFM XKRX:203690 ASX:MVF ROCO:4128 NAS:AFMD TPE:1720 NAS:CMRX XKRX:200670 NAS:AGLE NAS:GMDA XKRX:220250 XPAR:ALPHA NAS:VBIV NAS:SPRO NAS:NTEC XTAE:CGEN
Traded in other countries P6NA.Germany
Address 300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. The company's clinical pipeline includes two categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Ratios

Current vs industry vs history
PB Ratio 1.10
PB Ratio ranked lower than
83.16% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ACER: 1.1
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.96, Med: 3.23, Max: 11.23
Current: 1.1
0.96
11.23
EV-to-EBIT -0.38
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ACER: -0.38
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -12.1, Med: -1.7, Max: -0.1
Current: -0.38
-12.1
-0.1
EV-to-EBITDA -0.38
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ACER: -0.38
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -12.4, Med: -1.7, Max: -0.1
Current: -0.38
-12.4
-0.1
Current Ratio 10.92
Current Ratio ranked higher than
56.80% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ACER: 10.92
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 2.73, Max: 21.96
Current: 10.92
0.01
21.96
Quick Ratio 10.92
Quick Ratio ranked higher than
58.47% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ACER: 10.92
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 2.7, Max: 21.96
Current: 10.92
0.01
21.96

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -146.60
3-Year Share Buyback Rate ranked lower than
96.73% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ACER: -146.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -167.9, Med: -35.7, Max: 0
Current: -146.6
-167.9
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.38
Price-to-Tangible-Book ranked lower than
87.70% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ACER: 1.38
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.59, Med: 4.2, Max: 124.08
Current: 1.38
0.59
124.08
Earnings Yield (Joel Greenblatt) % -263.69
Earnings Yield (Greenblatt) ranked higher than
60.04% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ACER: -263.69
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3165.4, Med: -60.15, Max: 6658.8
Current: -263.69
-3165.4
6658.8

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N